Akebia Hit With Investor Suit Over Anemia Drug Disclosure
Kidney drug company Akebia Therapeutics Inc. is facing a shareholder suit that accuses it of misrepresenting the regulatory approval chances for an anemia therapy it had in the works, which an...To view the full article, register now.
Already a subscriber? Click here to view full article